BIOMARK Laboratories-INDIA

www.biomarklabs.com

TECHNICAL SHEET

B866	M-PA AGAR B	M-PA AGAR BASE							
Formula									
Ingredients:		gms/lit.							
L-lysine monohydrochloride		5.00							
Sodium chloride		5.00							
Yeast extract		2.00							
Xylose		2.50							
Sucrose		1.25							
Lactose		1.25							
Ferric ammonium citrate		0.80							
Sodium thiosulphate		6.80							
Phenol red		0.08							
Agar		15.00							
Final pH (at	25°C): 7.1 <u>+</u> 0.2								
Directions	:								
Suspend 30	68 grams in 1000	ml distilled wate	r Heat to hoiling to dissolve the medium completely						

Suspend 39.68 grams in 1000 ml. distilled water. Heat to boiling to dissolve the medium completely. Sterilize by autoclaving at 15 lbs pressure (121° C) for 15 minutes. Cool to 50°C and aseptically add 176 mg Sulphapyridine,8.5 mg Kanamycin, 37.0 mg Nalidixic acid and 150 mg Cycloheximide per litre of medium. Mix well and use as desired.

Principle:

L-Lysine, yeast extract and the three carbohydrates viz. lactose, sucrose and xylose provide nitrogenous nutrients, vitamins, carbonaceous compounds and energy sources for the metabolism of bacteria. Salts in the medium supply essential ions while sodium chloride maintains the osmotic equilibrium. Phenol red is the pH indicator which turns yellow at acidic pH. Kanamycin and Nalidixic acid inhibit gram - positive and gram -negative bacteria respectively. Kanamycin inhibits protein synthesis while Nalidixic acid blocks the replication of DNA of susceptible gram - negative bacteria. Cycloheximide suppresses the fungal contamination.

contamination.									
QC Tests - (I)D	ehydrated Med	ium							
Colour:			Orangish pink						
Appearance :			Homogeneous Free Flowing powder						
(II)Rehydrated									
pH (post autoclaving/heating) :			7.1 ± 0.2						
Colour (post a	Orange red								
Clarity (post autoclaving/heating):			Slightly opalescent						
(III) Q.C. Test N	Microbiological								
Cultural chara	cteristics observe	ed after a	n incubation	n at 4	41.5 ± 0.	.5°C for upto 72 hour	s after addition of		
Sulphapyridine, Kanamycin, Nalidixic acid and Cycloheximide									
MICROORGANISM (ATCC) GR			ROWTH		COLOUR OF MEDIUM				
Pseudomonas aeruginosa (27853) Go			ood-luxurian	t	Pink				
Escherichia coli (25922) Inl			hibited		-				
Klebsiella pneumoniae (13883) Inl			hibited		-				
Salmonella typhi (6539) In			hibited		-				
Staphylococcu	Staphylococcus aureus (25923) In				-				
Precautions:	1. For Laboratory Use.								
	2. Follow proper, established laboratory procedures in handling and disposing of								
	infectious materials.								
Limitations :	1. Since the nutritional requirements of organisms vary, some strains may be								
	encountered that fail to grow or grow poorly on this medium.								
Use :									
	Storage: Dehydrated medium- below 30°C Prepared medium- Between 2 to 8°C.								
Packing:	acking: 500 gm. bottle								
Product profile:	Reconstitution	Quantity		pН	(25°C)	Supplement	Sterilization		
			ion (500g)						
B866	39.68g/l	12	2.60L	7.3	1 ± 0.2		121ºC / 15		
						Sulphapyridine,	minutes		
						8.5mg Kanamycin,			
						37.0 mg Nalidixic			
						acid and 150 mg			
						Cycloheximide			
Refer disclaimer overle	af					Page 01 of 02			

Refer disclaimer overleaf Page 01 of 02

BIOMARK Laboratories-INDIA www.biomarklabs.com

TECHNICAL SHEET

Disclaimer:

User must ensure suitability of the product(s) in their application prior to use. Products conform solely to the information contained in this and other related BIOMARKLABORATORIES publications.

The information contained in this publication is based on our in-house studies and market performance and is to the best of our knowledge true and accurate. BIOMARK LABORATORIES reserves the right to make changes to specifications and information related to the products at any time. Products are not intended for human or animal or therapeutic use but for laboratory, diagnostic, research or further manufacturing use only, unless otherwise specified. Statements contained herein should not be considered as a warranty of any kind, expressed or implied, and no liability is accepted for infringement of any patents.

Page 02 of 02

Rev: December 2020